retatrutide type 2 diabetes trial 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 ๐จBreaking: Retatrutide's first Phase 3
Pay in 4 interest-free payments of $5.60 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Jul 31 - Aug 5


























